Figitumumab
(Synonyms: CP-751871) 目录号 : GC69112Figitumumab (CP-751871) 是一种有效的全人抗胰岛素样生长因子 1 受体 (IGF1R) 单克隆抗体。Figitumumab 可阻止 IGF1 与 IGF1R 结合,IC50 为 1.8 nM。
Cas No.:943453-46-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >96.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Figitumumab (CP-751871) is a potent and fully human monoclonal anti-insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM[1].
Figitumumab (CP-751871) (152 pM-10 μM; 3 days) inhibits cancer cell proliferation[1].
Figitumumab (1 μg/mL; 1 min or 24 h) induces the down-regulation of IGF-1R[2].
Figitumumab inhibits IGF1-induced autophosphorylation of IGF1R with an IC50 of 0.42 nM, and indirectly inhibits AKT activation[2].
Figitumumab recognizes the IGF-1R/IR heterodimer complex[2].
Cell Proliferation Assay[1]
Cell Line: | Breast, colon, lung small cell, and non-small cell cancer lines |
Concentration: | 152 pM-10 μM |
Incubation Time: | 3 days |
Result: | 15 cell lines (NCIH441, NCIH526, SW403, CACO2, SW48, NCIH524, SKCO1, SNUC1, LS1034, COLO205, MDAMB361, NCIH508, LS513, MCF7, NCIH378) were highly sensitive to the drug at IC50 values ≦ 100 nM. |
Western Blot Analysis[2]
Cell Line: | 3T3/IGF-1R cell |
Concentration: | 1 μg/mL |
Incubation Time: | 1 min or 24 h |
Result: | Blocked IGF-I- or IGF-II-induced autophosphorylation of the IGF-1R. |
Figitumumab (CP-751871) (31-125 μg/mouse; i.p.; once) induces the down-regulation of tumor associated IGF-1R in mice[2].
Figitumumab (62.5-500 μg/mouse; i.p.; once) inhibits the growth of s.c. xenografts derived from colon (Colo-205), breast (MCF7), and lung (H460) cancer cell lines in mice[2].
Animal Model: | Female atmic mice (CD-1 nu/nu) bearing NIH3T3/IGF-1R tumors[2] |
Dosage: | 31 to 125 μg per mouse |
Administration: | Intraperitoneal injection, once |
Result: | Resulted in a serum Cmax between 12 and 24 hours. At 24 hours, there was a dose-dependent reduction of IGF-1R protein in tumors, with 50% reduction observed at a serum concentration of 15 μg/mL. Resulted in a down-regulation of IGF-1R from the tumor. The half-life in an atmic mouse was determined to be 4 to 6 days by longer-term studies. |
Animal Model: | Female atmic mice (CD-1 nu/nu), human Colo-205 tumor xenograft model[2] |
Dosage: | 62.5 μg or 250 μg per mouse |
Administration: | Intraperitoneal injection, once |
Result: | Inhibited the tumor growth. |
[1]. Pavlicek A, et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol Cancer Ther. 2013 Dec;12(12):2929-39.
[2]. Cohen BD, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005 Mar 1;11(5):2063-73.
Cas No. | 943453-46-1 | SDF | Download SDF |
别名 | CP-751871 | ||
分子式 | 分子量 | ||
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。